Risk factors for ESRD in HIV-infected individuals: Traditional and HIV-related factors

American Journal of Kidney Diseases

Volumn 59, Issue 5, 2012, Pages 628-635

  Jotwani, Vasantha ^a,b   Li, Yongmei ^a   Grunfeld, Carl ^b   Choi, Andy I ^b   Shlipak, Michael G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic kidney disease; End stage renal disease; human immunodeficiency virus (HIV); risk factors

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; HYPOALBUMINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; VETERAN; VIRUS LOAD;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CHRONIC DISEASE; COHORT STUDIES; DIABETES COMPLICATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84859793974     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.10.050     Document Type: Article

References (44)

1. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(11):1559-1585. (Pubitemid 40720806)
2. Humphreys MH. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int. 1995;48(2):311-320.
3. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18(3):541-546. (Pubitemid 38365883)
4. Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS. 2004;18:1089-1099. (Pubitemid 38738508)
5. Eggers PW, Kimmel PL. Is there an epidemic of HIV infection in the US ESRD program? J Am Soc Nephrol. 2004;15:2477-2485. (Pubitemid 39159349)
6. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Am J Kidney Dis. 2011;57(1)(suppl 1):e1-e526.
7. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007;72(11):1380-1387. (Pubitemid 350126779)
8. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197(11):1548-1557. (Pubitemid 351706485)
9. Szczech LA, Grunfeld G, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS. 2007;21(8):1003-1009. (Pubitemid 46684331)
10. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195-202. (Pubitemid 34075147)
11. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199-1206. (Pubitemid 40169320)
12. Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23(1):71-82.
13. Tsui J, Vittinghoff E, Anastos K, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis. 2009;54(1):43-50.
14. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-1184. (Pubitemid 40720744)
15. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Diabetes Care. 2008;31(6):1224-1229.
16. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6(2):114-121. (Pubitemid 40425975)
17. Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007;21(18):2435-2443. (Pubitemid 350145175)
18. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145-1152. (Pubitemid 39121021)
19. Backus L, Mole L, Chang S, Deyton L. The Immunology Case Registry. J Clin Epidemiol. 2001;54(1)(suppl 1):S12-S15. (Pubitemid 34013686)
20. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121(5):651-658.
21. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010;78(5):478-485.
22. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care. 2004;27(2)(suppl 2):B22-B26. (Pubitemid 38569260)
23. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167(11):1130-1136. (Pubitemid 46919815)
24. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis. 2009;204(1):298-303.
25. Sohn MW, Zhang H, Arnold N, et al. Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. Popul Health Metr. 2006;4(7):7.
26. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
27. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(2)(suppl 2):B10-B21. (Pubitemid 38569259)
28. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005;19(3)(suppl 3):S99-S105. (Pubitemid 41682176)
29. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171. (Pubitemid 38428955)
30. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care. 2006;44(8)(suppl 2):S52-S60. (Pubitemid 44284258)
31. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-147.
32. Schoenfeld D. Residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
34. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74(8):994-997.
35. Newson RB. Comparing the predictive power of survival models using Harrell's C or Somer's D. Stata J. 2010;10:339-358.
36. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
37. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61:1-6. (Pubitemid 38100837)
38. Laradi A, Mallet A, Beaufils H, Allouache M, Martinez F. HIV-associated nephropathy: outcome and prognosis factors. Groupe d'Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol. 1998;9(12):2327-2335.
39. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14(11):2902-2907. (Pubitemid 37305653)
40. Rosset S, Tzur S, Behar DM,Wasser WG, Skorecki K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol. 2011;7(6):313-326.
41. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis. 2010;56(5):872-882.
42. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953-960. (Pubitemid 40834939)
43. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296. (Pubitemid 44837777)
44. Zingmond DS, Kilbourne AM, Justice AC, et al. Differences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr. 2003;33(suppl 2):S84-S92. (Pubitemid 36801606)